1. Home
  2. KBDC vs SPRY Comparison

KBDC vs SPRY Comparison

Compare KBDC & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kayne Anderson BDC Inc.

KBDC

Kayne Anderson BDC Inc.

HOLD

Current Price

$14.52

Market Cap

1.0B

Sector

N/A

ML Signal

HOLD

Logo ARS Pharmaceuticals Inc.

SPRY

ARS Pharmaceuticals Inc.

HOLD

Current Price

$10.23

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KBDC
SPRY
Founded
2021
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KBDC
SPRY
Price
$14.52
$10.23
Analyst Decision
Buy
Strong Buy
Analyst Count
5
2
Target Price
$15.80
$35.00
AVG Volume (30 Days)
319.3K
1.7M
Earning Date
03-02-2026
11-10-2025
Dividend Yield
13.06%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$142,772,000.00
Revenue This Year
$193.84
N/A
Revenue Next Year
$9.00
$126.72
P/E Ratio
N/A
N/A
Revenue Growth
N/A
5459.66
52 Week Low
$13.06
$6.66
52 Week High
$17.99
$18.90

Technical Indicators

Market Signals
Indicator
KBDC
SPRY
Relative Strength Index (RSI) 44.99 44.68
Support Level $14.47 $10.02
Resistance Level $14.93 $11.93
Average True Range (ATR) 0.36 0.71
MACD 0.00 -0.21
Stochastic Oscillator 36.74 6.55

Price Performance

Historical Comparison
KBDC
SPRY

About KBDC Kayne Anderson BDC Inc.

Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Share on Social Networks: